|
KR20060054196A
(en)
*
|
2003-06-10 |
2006-05-22 |
주식회사 툴젠 |
Transducible dna-binding protein
|
|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
WO2005014791A2
(en)
|
2003-08-08 |
2005-02-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
WO2005028630A2
(en)
|
2003-09-19 |
2005-03-31 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
ATE540111T1
(en)
|
2003-11-05 |
2012-01-15 |
Int Inst Cancer Immunology Inc |
HLA-DR BINDING ANTIGEN PEPTIDE DERIVED FROM WT1
|
|
DE102005026163A1
(en)
*
|
2004-08-24 |
2006-03-02 |
Dade Behring Marburg Gmbh |
Antibodies directed against the Marburg I polymorphism of Factor VII activating protease (FSAP), their production and use
|
|
WO2006033859A2
(en)
|
2004-09-16 |
2006-03-30 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
|
EP1913149A4
(en)
|
2005-07-26 |
2009-08-05 |
Sangamo Biosciences Inc |
Targeted integration and expression of exogenous nucleic acid sequences
|
|
AU2007267887B2
(en)
|
2006-05-25 |
2013-05-30 |
Sangamo Therapeutics, Inc. |
Variant Foki Cleavage Half-Domains
|
|
US7951925B2
(en)
|
2006-05-25 |
2011-05-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene inactivation
|
|
ES2532002T3
(en)
|
2006-08-11 |
2015-03-23 |
Dow Agrosciences Llc |
Homologous nuclease-mediated recombination with zinc fingers
|
|
EP2089427B1
(en)
|
2006-11-13 |
2014-07-30 |
Sangamo BioSciences, Inc. |
Zinc finger nuclease for targeting the human glucocorticoid receptor locus
|
|
SI2092068T1
(en)
|
2006-12-14 |
2015-06-30 |
Dow Agrosciences Llc |
Optimized non-canonical zinc finger proteins
|
|
MY164867A
(en)
|
2007-02-27 |
2018-01-30 |
Int Inst Cancer Immunology Inc |
Method for activation of helper t cell and composition for use in the method
|
|
WO2008133938A2
(en)
|
2007-04-26 |
2008-11-06 |
Sangamo Biosciences, Inc. |
Targeted integration into the ppp1r12c locus
|
|
WO2009006297A2
(en)
|
2007-06-29 |
2009-01-08 |
Pioneer Hi-Bred International, Inc. |
Methods for altering the genome of a monocot plant cell
|
|
CN101883850B
(en)
|
2007-07-12 |
2014-11-12 |
桑格摩生物科学股份有限公司 |
Methods and compositions for inactivating alpha-1,6 fucosyltransferase (FUT 8) gene expression
|
|
PT2205749T
(en)
|
2007-09-27 |
2016-07-20 |
Dow Agrosciences Llc |
Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
JP5763341B2
(en)
|
2007-09-27 |
2015-08-12 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Rapid in vivo identification of biologically active nucleases
|
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
|
US20110014616A1
(en)
|
2009-06-30 |
2011-01-20 |
Sangamo Biosciences, Inc. |
Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
|
|
WO2009054985A1
(en)
|
2007-10-25 |
2009-04-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted integration
|
|
AU2009238629C1
(en)
|
2008-04-14 |
2015-04-30 |
Sangamo Therapeutics, Inc. |
Linear donor constructs for targeted integration
|
|
CA2725773C
(en)
|
2008-05-28 |
2017-12-05 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
EP2130836B1
(en)
*
|
2008-06-03 |
2013-02-13 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Means and methods for producing zinc fingers and concatemers thereof
|
|
WO2009151591A2
(en)
|
2008-06-10 |
2009-12-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
|
SG10201609144RA
(en)
|
2008-08-22 |
2016-12-29 |
Sangamo Biosciences Inc |
Methods and compositions for targeted single-stranded cleavage and targeted integration
|
|
US8153399B2
(en)
|
2008-10-29 |
2012-04-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating glutamine synthetase gene expression
|
|
EP2352369B1
(en)
|
2008-12-04 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Genome editing in rats using zinc-finger nucleases
|
|
JP2012511926A
(en)
|
2008-12-17 |
2012-05-31 |
ダウ・アグロサイエンス・エル・エル・シー |
Targeted integration into the ZP15 locus
|
|
EP2393506B1
(en)
|
2009-02-04 |
2018-03-28 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating neuropathies
|
|
CA2755192C
(en)
|
2009-03-20 |
2018-09-11 |
Sangamo Biosciences, Inc. |
Modification of cxcr4 using engineered zinc finger proteins
|
|
CA2756833C
(en)
|
2009-04-09 |
2019-11-19 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
|
US8772008B2
(en)
|
2009-05-18 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for increasing nuclease activity
|
|
JP5866283B2
(en)
|
2009-07-28 |
2016-02-17 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Methods and compositions for treating trinucleotide repeat disease
|
|
US20110041195A1
(en)
|
2009-08-11 |
2011-02-17 |
Sangamo Biosciences, Inc. |
Organisms homozygous for targeted modification
|
|
ES2657067T3
(en)
|
2009-10-22 |
2018-03-01 |
Dow Agrosciences Llc |
Genetically modified zinc finger proteins that target plant genes involved in fatty acid biosynthesis
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
WO2011082310A2
(en)
|
2009-12-30 |
2011-07-07 |
Pioneer Hi-Bred International, Inc. |
Methods and compositions for targeted polynucleotide modification
|
|
MX336846B
(en)
|
2010-01-22 |
2016-02-03 |
Sangamo Biosciences Inc |
Targeted genomic alteration.
|
|
EP2534173B1
(en)
|
2010-02-08 |
2019-09-11 |
Sangamo Therapeutics, Inc. |
Engineered cleavage half-domains
|
|
US9255259B2
(en)
|
2010-02-09 |
2016-02-09 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
JP5952263B2
(en)
|
2010-04-26 |
2016-07-13 |
サンガモ バイオサイエンシーズ， インコーポレイテッド |
Genome editing of the ROSA locus using zinc finger nuclease
|
|
US8772453B2
(en)
|
2010-05-03 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Compositions for linking zinc finger modules
|
|
EP2571512B1
(en)
|
2010-05-17 |
2017-08-23 |
Sangamo BioSciences, Inc. |
Novel dna-binding proteins and uses thereof
|
|
CA3157027A1
(en)
|
2010-07-21 |
2012-01-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a t-cell receptor gene
|
|
EP2622090B1
(en)
|
2010-09-27 |
2019-06-19 |
Sangamo Therapeutics, Inc. |
Compositions for inhibiting viral entry into cells
|
|
TWI608099B
(en)
|
2010-10-05 |
2017-12-11 |
癌免疫研究所股份有限公司 |
Method and composition for activating cytotoxic t cells, and an activation inducer of cytotoxic t cells
|
|
CA2814143C
(en)
|
2010-10-12 |
2020-09-08 |
The Children's Hospital Of Philadelphia |
Methods and compositions for treating hemophilia b
|
|
WO2012094132A1
(en)
|
2011-01-05 |
2012-07-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
|
IN2013MN01582A
(en)
|
2011-01-20 |
2015-06-12 |
Oneday Biotech And Pharma Ltd |
|
|
CN103842511A
(en)
|
2011-03-23 |
2014-06-04 |
先锋国际良种公司 |
Methods for producing a complex transgenic trait locus
|
|
SG194089A1
(en)
|
2011-04-27 |
2013-11-29 |
Amyris Inc |
Methods for genomic modification
|
|
EA201490056A1
(en)
|
2011-06-21 |
2014-05-30 |
Пайонир Хай-Бред Интернэшнл, Инк. |
METHODS AND COMPOSITIONS FOR OBTAINING PLANTS OWNED BY MALE STERILITY
|
|
WO2013012674A1
(en)
|
2011-07-15 |
2013-01-24 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
|
AU2012286901B2
(en)
|
2011-07-25 |
2016-10-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
|
IL293650B1
(en)
|
2011-09-21 |
2024-06-01 |
Sangamo Therapeutics Inc |
Methods and compositions for regulation of transgene expression
|
|
WO2013063315A2
(en)
|
2011-10-27 |
2013-05-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
JP6144691B2
(en)
|
2011-11-16 |
2017-06-07 |
サンガモ セラピューティクス， インコーポレイテッド |
Modified DNA binding proteins and uses thereof
|
|
JP6490426B2
(en)
|
2012-02-29 |
2019-03-27 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for treating Huntington's disease
|
|
WO2013166315A1
(en)
|
2012-05-02 |
2013-11-07 |
Dow Agrosciences Llc |
Targeted modification of malate dehydrogenase
|
|
WO2013169802A1
(en)
|
2012-05-07 |
2013-11-14 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
EP2872154B1
(en)
|
2012-07-11 |
2017-05-31 |
Sangamo BioSciences, Inc. |
Methods and compositions for delivery of biologics
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
EP3196301B1
(en)
|
2012-07-11 |
2018-10-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of monogenic diseases
|
|
CN104717970A
(en)
|
2012-07-23 |
2015-06-17 |
万德-生物技术及制药有限公司 |
Glutathione-elevating compositions and uses thereof
|
|
WO2014016837A1
(en)
|
2012-07-25 |
2014-01-30 |
Oneday - Biotech And Pharma Ltd. |
Compositions and methods for increasing carnitine level in muscle tissues
|
|
SG10201701601WA
(en)
|
2012-08-29 |
2017-04-27 |
Sangamo Biosciences Inc |
Methods and compositions for treatment of a genetic condition
|
|
UA118090C2
(en)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
|
EP3406715B1
(en)
|
2012-09-07 |
2023-12-13 |
Corteva Agriscience LLC |
Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
|
UA119135C2
(en)
|
2012-09-07 |
2019-05-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Engineered transgene integration platform (etip) for gene targeting and trait stacking
|
|
HUE050797T2
(en)
|
2012-10-10 |
2021-01-28 |
Sangamo Therapeutics Inc |
T cell modifying compounds and uses thereof
|
|
US20150267176A1
(en)
|
2012-10-12 |
2015-09-24 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
EP2929017A4
(en)
|
2012-12-05 |
2016-09-28 |
Sangamo Biosciences Inc |
Methods and compositions for regulation of metabolic disorders
|
|
AR093980A1
(en)
|
2012-12-13 |
2015-07-01 |
Dow Agrosciences Llc |
PRECISION GENES THAT HAVE A PARTICULAR LOCUS IN THE CORN AS THE OBJECTIVE
|
|
SG10201705028WA
(en)
|
2012-12-17 |
2017-07-28 |
Otsuka Pharma Co Ltd |
Method for activating helper t cell
|
|
WO2014124284A1
(en)
|
2013-02-07 |
2014-08-14 |
The General Hospital Corporation |
Tale transcriptional activators
|
|
WO2014130955A1
(en)
|
2013-02-25 |
2014-08-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
CA2906970C
(en)
|
2013-03-21 |
2021-05-18 |
Ospedale San Raffaele Srl |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
KR102192599B1
(en)
|
2013-04-05 |
2020-12-18 |
다우 아그로사이언시즈 엘엘씨 |
Methods and compositions for integration of an exogenous sequence within the genome of plants
|
|
WO2014182700A1
(en)
|
2013-05-10 |
2014-11-13 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
CA2910489A1
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
EP3039136B8
(en)
|
2013-08-28 |
2020-12-16 |
Sangamo Therapeutics, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
CN105899665B
(en)
|
2013-10-17 |
2019-10-22 |
桑格摩生物科学股份有限公司 |
The delivering method and composition being transformed for nuclease-mediated genome project
|
|
CA2926078C
(en)
|
2013-10-17 |
2021-11-16 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
UY35815A
(en)
|
2013-11-04 |
2015-05-29 |
Dow Agrosciences Llc |
? OPTIMAL LOCKS OF CORN?
|
|
TW201518504A
(en)
|
2013-11-04 |
2015-05-16 |
Dow Agrosciences Llc |
Optimal maize loci
|
|
TWI672378B
(en)
|
2013-11-04 |
2019-09-21 |
陶氏農業科學公司 |
Optimal soybean loci
|
|
WO2015066634A2
(en)
|
2013-11-04 |
2015-05-07 |
Dow Agrosciences Llc |
Optimal soybean loci
|
|
RU2693891C1
(en)
|
2013-11-11 |
2019-07-05 |
Сангамо Байосайенсиз, Инк. |
Methods and compositions for treating huntington's disease
|
|
PL3068881T3
(en)
|
2013-11-13 |
2019-08-30 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
|
AU2014364051B2
(en)
|
2013-12-09 |
2018-12-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating hemophilia
|
|
CN106029886B
(en)
|
2013-12-19 |
2021-02-05 |
阿迈瑞斯公司 |
Method for genomic integration
|
|
JP6606088B2
(en)
|
2014-02-24 |
2019-11-13 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for nuclease-mediated targeted integration
|
|
CA2942762C
(en)
|
2014-03-18 |
2023-10-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
|
CN106413760B
(en)
|
2014-05-08 |
2020-01-14 |
桑格摩生物科学股份有限公司 |
Methods and compositions for treating huntington's disease
|
|
CA2947622A1
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Genome editing methods and compositions for prevention or treatment of a disease
|
|
EP3151846A4
(en)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for nuclease design
|
|
EP3166964A1
(en)
|
2014-07-08 |
2017-05-17 |
Vib Vzw |
Means and methods to increase plant yield
|
|
NZ728159A
(en)
|
2014-07-14 |
2018-08-31 |
Univ Washington State |
Nanos2 knock-out that ablates germline cells
|
|
US11278572B2
(en)
|
2014-07-18 |
2022-03-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
|
|
US9757420B2
(en)
|
2014-07-25 |
2017-09-12 |
Sangamo Therapeutics, Inc. |
Gene editing for HIV gene therapy
|
|
WO2016014794A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
LT3194570T
(en)
|
2014-09-16 |
2021-09-27 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
EP3247366A4
(en)
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
ES2959608T3
(en)
|
2015-04-03 |
2024-02-27 |
Dana Farber Cancer Inst Inc |
Composition and editing methods of the B cell genome
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
US10808020B2
(en)
|
2015-05-12 |
2020-10-20 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
EP3322297A4
(en)
|
2015-07-13 |
2019-04-17 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
JP6993318B2
(en)
*
|
2015-07-15 |
2022-02-03 |
エージェンシー フォー サイエンス，テクノロジー アンド リサーチ |
Regulation of hepatitis B virus replication
|
|
FI3331355T3
(en)
|
2015-08-06 |
2024-06-17 |
Univ Missouri |
Porcine reproductive and respiratory syndrome virus (prrsv)-resistant porcine and cells having modified cd163 genes
|
|
MX2018003491A
(en)
|
2015-09-23 |
2018-09-06 |
Sangamo Therapeutics Inc |
Htt repressors and uses thereof.
|
|
JP6976249B2
(en)
|
2015-11-23 |
2021-12-08 |
サンガモ セラピューティクス， インコーポレイテッド |
Methods and compositions for engineering immunity
|
|
CN108699132B
(en)
|
2015-12-18 |
2023-08-11 |
桑格摩生物治疗股份有限公司 |
Targeted disruption of MHC cell receptors
|
|
AU2016369490C1
(en)
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
WO2017123757A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
CN109069568B
(en)
|
2016-02-02 |
2023-07-07 |
桑格摩生物治疗股份有限公司 |
Compositions for linking DNA binding domains and cleavage domains
|
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
|
EP3429567B1
(en)
|
2016-03-16 |
2024-01-10 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
|
EP3433362B1
(en)
|
2016-03-23 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
|
US11293033B2
(en)
|
2016-05-18 |
2022-04-05 |
Amyris, Inc. |
Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
|
|
AU2017295720B2
(en)
|
2016-07-13 |
2021-07-22 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
CA3031818A1
(en)
|
2016-07-27 |
2018-02-01 |
Case Western Reserve University |
Compounds and methods of promoting myelination
|
|
JP7066126B2
(en)
|
2016-08-09 |
2022-05-13 |
ブイアイビー ブイゼットダブリュ |
Cellulose synthase inhibitors and mutant plants
|
|
TN2019000048A1
(en)
|
2016-08-24 |
2020-07-15 |
Sangamo Therapeutics Inc |
Regulation of gene expression using engineered nucleases.
|
|
IL264792B2
(en)
|
2016-08-24 |
2023-10-01 |
Sangamo Therapeutics Inc |
Engineered target-specific zinc finger nucleases
|
|
WO2018049009A2
(en)
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
WO2018067697A1
(en)
|
2016-10-04 |
2018-04-12 |
Precision Biosciences, Inc. |
Co-stimulatory domains for use in genetically-modified cells
|
|
CN110022904B
(en)
|
2016-10-20 |
2024-04-19 |
桑格摩生物治疗股份有限公司 |
Methods and compositions for treating brile disease
|
|
EP3532106A4
(en)
|
2016-10-31 |
2020-06-24 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
CN110214184B
(en)
|
2016-12-01 |
2024-07-02 |
桑格摩生物治疗股份有限公司 |
Tau modulators and methods and compositions for delivery thereof
|
|
CA3046199A1
(en)
|
2016-12-08 |
2018-06-14 |
Case Western Reserve University |
Methods and compositions for enhancing functional myelin production
|
|
US20180179553A1
(en)
|
2016-12-14 |
2018-06-28 |
Ligandal, Inc. |
Compositions and methods for nucleic acid and/or protein payload delivery
|
|
AU2018255975A1
(en)
|
2017-04-20 |
2019-08-15 |
Oregon Health & Science University |
Human gene correction
|
|
EP3619322A4
(en)
|
2017-05-03 |
2021-06-30 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
WO2018208837A1
(en)
|
2017-05-08 |
2018-11-15 |
Precision Biosciences, Inc. |
Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
US11053484B2
(en)
|
2017-06-30 |
2021-07-06 |
Precision Biosciences, Inc. |
Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene
|
|
JP2020537515A
(en)
|
2017-10-03 |
2020-12-24 |
ジュノー セラピューティクス インコーポレイテッド |
HPV-specific binding molecule
|
|
WO2019070856A1
(en)
|
2017-10-03 |
2019-04-11 |
Precision Biosciences, Inc. |
Modified epidermal growth factor receptor peptides for use in genetically-modified cells
|
|
US20200299658A1
(en)
|
2017-11-01 |
2020-09-24 |
Precision Biosciences, Inc. |
Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
|
|
IL274323B1
(en)
|
2017-11-09 |
2024-06-01 |
Sangamo Therapeutics Inc |
Genetic modification of cytokine inducible sh2-containing protein (cish) gene
|
|
KR20200109358A
(en)
|
2018-01-17 |
2020-09-22 |
버텍스 파마슈티칼스 인코포레이티드 |
DNA-PK inhibitor
|
|
EP3740480B1
(en)
|
2018-01-17 |
2024-03-06 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
|
IL276081B2
(en)
|
2018-01-17 |
2023-10-01 |
Vertex Pharma |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
|
MX2020008272A
(en)
|
2018-02-08 |
2020-09-21 |
Sangamo Therapeutics Inc |
Engineered target specific nucleases.
|
|
BR112020020245A2
(en)
|
2018-04-05 |
2021-04-06 |
Editas Medicine, Inc. |
METHODS OF PRODUCING CELLS EXPRESSING A RECOMBINANT RECEIVER AND RELATED COMPOSITIONS
|
|
AU2019247199A1
(en)
|
2018-04-05 |
2020-10-15 |
Editas Medicine, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2019204457A1
(en)
|
2018-04-18 |
2019-10-24 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (htt)
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
WO2020041249A1
(en)
|
2018-08-23 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
|
KR20210060533A
(en)
|
2018-09-18 |
2021-05-26 |
상가모 테라퓨틱스, 인코포레이티드 |
Programmed cell death 1 (PD1) specific nuclease
|
|
US20220090047A1
(en)
|
2018-12-21 |
2022-03-24 |
Precision Biosciences, Inc. |
Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
|
|
CA3125485A1
(en)
|
2019-01-11 |
2020-07-16 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CA3106693A1
(en)
|
2019-02-06 |
2020-08-13 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type i
|
|
WO2020163856A1
(en)
|
2019-02-10 |
2020-08-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Modified mitochondrion and methods of use thereof
|
|
US20200316116A1
(en)
|
2019-04-02 |
2020-10-08 |
Sangamo Therapeutics, Inc. |
Method for the treatment of beta-thalassemia
|
|
MX2021012110A
(en)
|
2019-04-03 |
2022-01-06 |
Prec Biosciences Inc |
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir).
|
|
US20220204994A1
(en)
|
2019-04-05 |
2022-06-30 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
CN113766921A
(en)
|
2019-04-23 |
2021-12-07 |
桑格摩生物治疗股份有限公司 |
Regulator for chromosome 9 open reading frame 72 gene expression and its use
|
|
CN114007640A
(en)
|
2019-05-01 |
2022-02-01 |
朱诺治疗学股份有限公司 |
Cells expressing chimeric receptors from modified CD247 loci, related polynucleotides and methods
|
|
BR112021021075A2
(en)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
EP4004216A1
(en)
|
2019-07-25 |
2022-06-01 |
Precision BioSciences, Inc. |
Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
|
|
EP4017526A1
(en)
|
2019-08-20 |
2022-06-29 |
Precision BioSciences, Inc. |
Lymphodepletion dosing regimens for cellular immunotherapies
|
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2021067871A1
(en)
|
2019-10-02 |
2021-04-08 |
Sangamo Therapeutics, Inc. |
Zinc finger protein transcription factors for repressing alpha-synuclein expression
|
|
US20230002459A1
(en)
|
2019-10-02 |
2023-01-05 |
Sangamo Therapeutics, Inc. |
Zinc Finger Protein Transcription Factors for Treatment of Prion Disease
|
|
WO2021087305A1
(en)
|
2019-10-30 |
2021-05-06 |
Precision Biosciences, Inc. |
Cd20 chimeric antigen receptors and methods of use for immunotherapy
|
|
TW202132565A
(en)
|
2019-11-01 |
2021-09-01 |
美商聖加莫治療股份有限公司 |
Gin recombinase variants
|
|
US20230036065A1
(en)
|
2019-12-06 |
2023-02-02 |
Precision Biosciences, Inc. |
Methods for cancer immunotherapy
|
|
TW202134288A
(en)
|
2020-01-22 |
2021-09-16 |
美商聖加莫治療股份有限公司 |
Zinc finger protein transcription factors for repressing tau expression
|
|
WO2021158915A1
(en)
|
2020-02-06 |
2021-08-12 |
Precision Biosciences, Inc. |
Recombinant adeno-associated virus compositions and methods for producing and using the same
|
|
WO2021202513A1
(en)
|
2020-03-31 |
2021-10-07 |
Elo Life Systems |
Modulation of endogenous mogroside pathway genes in watermelon and other cucurbits
|
|
EP4146812A1
(en)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
|
EP4146284A1
(en)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
|
US20230183664A1
(en)
|
2020-05-11 |
2023-06-15 |
Precision Biosciences, Inc. |
Self-limiting viral vectors encoding nucleases
|
|
EP4150057A2
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
JP2023531531A
(en)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
Engineered T Cells Conditionally Expressing Recombinant Receptors, Related Polynucleotides, and Methods
|
|
CA3189338A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
WO2022035793A1
(en)
|
2020-08-10 |
2022-02-17 |
Precision Biosciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
|
WO2022046760A2
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
AU2021350099A1
(en)
|
2020-09-25 |
2023-04-27 |
Sangamo Therapeutics, Inc. |
Zinc finger fusion proteins for nucleobase editing
|
|
WO2022072826A1
(en)
|
2020-10-02 |
2022-04-07 |
Sangamo Therapeutics, Inc. |
Novel zinc finger protein transcription factors for repressing alpha-synuclein expression
|
|
WO2022076547A1
(en)
|
2020-10-07 |
2022-04-14 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
EP4232461A1
(en)
|
2020-10-23 |
2023-08-30 |
ELO Life Systems, Inc. |
Methods for producing vanilla plants with improved flavor and agronomic production
|
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
CA3200855A1
(en)
|
2020-11-16 |
2022-05-19 |
Pig Improvement Company Uk Limited |
Influenza a-resistant animals having edited anp32 genes
|
|
WO2022165111A1
(en)
|
2021-01-28 |
2022-08-04 |
Precision Biosciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
|
US20240141311A1
(en)
|
2021-04-22 |
2024-05-02 |
North Carolina State University |
Compositions and methods for generating male sterile plants
|
|
WO2023064872A1
(en)
|
2021-10-14 |
2023-04-20 |
Precision Biosciences, Inc. |
Combinations of anti-bcma car t cells and gamma secretase inhibitors
|
|
AU2022371430A1
(en)
|
2021-10-19 |
2024-05-30 |
Precision Biosciences, Inc. |
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
WO2023091910A1
(en)
|
2021-11-16 |
2023-05-25 |
Precision Biosciences, Inc. |
Methods for cancer immunotherapy
|
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
|
AU2022421236A1
(en)
|
2021-12-22 |
2024-06-27 |
Sangamo Therapeutics, Inc. |
Novel zinc finger fusion proteins for nucleobase editing
|
|
WO2023131616A1
(en)
|
2022-01-05 |
2023-07-13 |
Vib Vzw |
Means and methods to increase abiotic stress tolerance in plants
|
|
WO2023131637A1
(en)
|
2022-01-06 |
2023-07-13 |
Vib Vzw |
Improved silage grasses
|
|
WO2023144199A1
(en)
|
2022-01-26 |
2023-08-03 |
Vib Vzw |
Plants having reduced levels of bitter taste metabolites
|
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024161021A1
(en)
|
2023-02-03 |
2024-08-08 |
Juno Therapeutics Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|